Pharmacokinetic study of HP-6050

JRCT ID: jRCT2031220536

Registered date:25/12/2022

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Healthy adult and elderly
• Date of first enrollment: 12/01/2023
• Target sample size: 60
• Study type: Interventional

Intervention(s)

Healthy adult: Single dose of HP-6050
Healthy elderly: Single dose of HP-6050

Outcome(s)

• Primary Outcome: Pharmacokinetic parameters, adverse events
• Secondary Outcome: Pharmacodynamics

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: Not applicable
• Gender: Both
• Include criteria: - Healthy Japanese adults aged >=18 and <65 years, or healthy Japanese elderly aged >=65 years (at the time of informed consent)

Exclude criteria

- Subjects with current or history of serious cardiac, vascular, renal, hepatic, psychiatric/neurological, or metabolic diseases
- Subjects who received any drug within a week prior to application of the study drug

Related Information

• Primary Sponsor: Inakura Hiroshi